A cosmetic composition and a method for minimizing skin blemishes

Abstract

The present disclosure relates to the field of cosmetic and / or dermatological compositions. More specifically, the present disclosure relates to novel cosmetic and / or dermatological compositions and methods for reducing skin drawbacks.

Description

Technical Field

[0001] This disclosure relates to the field of cosmetic and / or dermatological compositions. More specifically, this disclosure relates to novel cosmetic and / or dermatological compositions and methods for reducing skin imperfections. Background Technology

[0002] The cosmetics industry is constantly seeking innovative solutions to improve skin quality and address common skin problems such as uneven skin tone, pigmentation, and skin imperfections. One of the most common skin problems people face is yellowing and dullness, which can be caused by a variety of factors, including sun damage, aging, and genetics. Yellowing can be particularly problematic for people with darker skin tones, as it can make the complexion appear dull and lackluster. Furthermore, skin imperfections such as blemishes, acne scars, and age spots can also affect an individual's confidence and self-esteem.

[0003] Typically, to correct yellowing skin, a common practice is to use small amounts of blue or purple dyes to enhance the visual impression of whiteness. These dyes absorb light in the green-yellow region of the spectrum, causing the yellowish skin tone to shift towards blue, making the whiteness perceived by the human eye increase. However, because the overall reflected light is reduced, the perceived brightness is also decreased. Optical brighteners absorb invisible ultraviolet light and use their fluorescent properties to re-emit visible light. Unlike dyes, optical brighteners counteract yellow projection and simultaneously increase brightness because their bluish effect is based on increasing blue light, not subtracting yellow-green light.

[0004] US9545371B2 discloses a photoactivation system comprising a wide range of natural or synthetic fluorescent compounds.

[0005] CN113677367 A, CN113747875 A, and CN113692288 A all relate to technologies that convert ultraviolet light into visible light using ultraviolet wavelength conversion materials, and list zinc oxide phosphors, magnesium titanate phosphors, phycocyanin, phycoerythrin, and phycoerythrin as ultraviolet wavelength conversion materials.

[0006] However, the long-term use of chemicals such as zinc oxide poses potential safety concerns, and the need to develop safer and more effective skin care methods remains urgent. Summary of the Invention

[0007] In view of the above, the inventors have developed a novel cosmetic composition comprising an extract of *Eysenhardtia polystachya* (EP) that emits blue light to reduce skin yellowing and brighten the complexion, while also minimizing the appearance of skin imperfections. This technology provides a unique skincare approach that is both effective and safe.

[0008] The inventors unexpectedly discovered that, when used in combination with a specific fluorescence enhancer, the fluorescence and skin-brightening effects of EP extract can be significantly enhanced. Based on the above discovery, this disclosure provides the following aspects.

[0009] In one aspect, this disclosure provides a cosmetic composition comprising *Essencephalotaxus fortunei* extract and at least one fluorescence enhancer selected from sodium hydroxide, urea, betaine, nicotinamide, chitosan, histidine, lysine, matrine, polylysine, and arginine.

[0010] According to some implementation schemes, the extract of *Eisenia fetida* is selected from the flower extract, fruit extract, stem extract, leaf extract, and root extract of *Eisenia fetida*.

[0011] Preferably, the extract of *Essencephalotaxus fortunei* is a stem extract of *Essencephalotaxus fortunei*.

[0012] More preferably, the stem extract of *Essencephalotaxus fortunei* is a bark extract of *Essencephalotaxus fortunei*.

[0013] According to some implementation schemes, the extract of *Essencephalotaxus fortunei* is obtained by extraction using a solvent selected from lower saturated alkyl alcohols, water, and mixtures thereof.

[0014] Preferably, the extract of *Eisenia fetida* is obtained by extraction using a solvent selected from methanol, ethanol, ethylene glycol, propylene glycol, butylene glycol, glycerol, water, and mixtures thereof.

[0015] More preferably, the extract of *Eisenia fetida* is obtained by extraction using a mixture of propylene glycol and water as a solvent. Preferably, the ratio of propylene glycol to water in the mixture is about 1:10 to about 10:1, more preferably about 1:5 to about 5:1, and more preferably about 1:2 to about 2:1.

[0016] According to some implementation schemes, the fluorescence enhancer is at least one selected from histidine, lysine, matrine, polylysine, and arginine.

[0017] Preferably, the fluorescence enhancer is at least one selected from lysine, matrine, polylysine, and arginine.

[0018] According to some embodiments, the cosmetic composition has a weight ratio of *Essencephalotaxus fortunei* extract to a fluorescence enhancer of about 5000:1 to about 1:100, preferably about 500:1 to about 1:10, and more preferably about 50:1 to about 1:1.

[0019] According to some embodiments, based on the total weight of the cosmetic composition, the extract of *Essencephalotaxus fortunei* has a content of about 0.001% by weight to about 50% by weight, preferably about 0.01% by weight to about 10% by weight, and more preferably about 0.1% by weight to about 2% by weight.

[0020] According to some embodiments, based on the total weight of the cosmetic composition, at least one fluorescent enhancer has a content of about 0.0001% by weight to about 50% by weight, preferably about 0.001% by weight to about 10% by weight, and more preferably about 0.01% by weight to about 2% by weight.

[0021] According to some embodiments, the cosmetic composition further comprises at least one cosmetically acceptable active ingredient selected from moisturizers, antioxidants, UV shielding agents, anti-inflammatory agents, preservatives, vitamins, skin conditioning agents, stabilizers, and mixtures thereof.

[0022] On the other hand, this disclosure provides cosmetics comprising cosmetic compositions according to this disclosure.

[0023] In another aspect, this disclosure provides the use of the cosmetic composition according to this disclosure in the manufacture of cosmetics for reducing the visual perception of skin imperfections, said skin imperfections being selected from yellowing, dullness, uneven skin tone, dark circles, pigmentation, rosacea, fine lines, wrinkles, enlarged pores, and cellulite.

[0024] In another aspect, this disclosure provides a cosmetic method for reducing the visual perception of skin imperfections, said skin imperfections being selected from yellowing, dullness, uneven skin tone, dark circles, pigmentation, rosacea, fine lines, wrinkles, enlarged pores, and cellulite, said method comprising topically applying a composition according to this disclosure to the skin.

[0025] Compared to the fluorescence emitted when used alone, the fluorescence emitted by the EP extract is significantly enhanced, by 10 times or more, when used in combination with a specific fluorescence enhancer according to this disclosure. Therefore, excellent fluorescence enhancement and skin brightening effects can be achieved, and the visual perception of skin imperfections can be safely and effectively reduced.

[0026] Other subjects, features, aspects and advantages of the present invention will become more apparent after reading the following description and examples. Attached Figure Description

[0027] The accompanying drawings are provided to further illustrate embodiments of the invention and form part of the specification. They are used together with the following detailed description of the invention to illustrate embodiments, but do not constitute a limitation thereof. In the drawings:

[0028] Figure 1 The absorption and emission spectra of the extract from *Essencephalotaxus fortunei* are shown. Detailed Implementation Plan

[0029] definition

[0030] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. In the event of any conflict between the definitions of terms in this specification and the common understanding of one of ordinary skill in the art to which this disclosure pertains, the definitions described herein shall prevail.

[0031] As used herein, the term "comprising" should be interpreted to encompass all specifically mentioned features as well as optional, additional, or unspecified features. As used herein, the use of the term "comprising" also discloses embodiments of features not present in the text (i.e., "consisting of").

[0032] Unless otherwise stated, as used herein, “molecular weight” refers to weight-average molecular weight.

[0033] Unless otherwise specified, all numerical values ​​used in the specification and claims to represent quantities, etc., should be understood to be modified by the term "about" and have a meaning conventionally known in the art, such as being within 10% of the indicated value (e.g., "about 100 to 220" means 90 to 242, and "about 10" means 9 to 11). Therefore, unless otherwise stated, the numerical values ​​and parameters described herein are approximate and may be changed as needed for the desired purpose. At a minimum, each numerical parameter should be interpreted based at least on the reported significant figures and with the application of conventional rounding techniques. Furthermore, the scope described in this disclosure and claims is intended to specifically include the entire range, not just the endpoints. For example, the range 0 to 10 is intended to disclose all integers between 0 and 10, such as 1, 2, 3, 4, and any subranges formed by any two of their values, all fractions between 0 and 10, such as 1.5, 2.3, 4.57, 6.1113, and any subranges formed by any two of their values, and the endpoints 0 and 10.

[0034] As used herein, the term "cosmetically acceptable" means that the ingredient described by the term is suitable for direct contact with human tissues, including hair and skin, without causing adverse effects such as allergic reactions, irritation, or undue toxicity.

[0035] As used in this article, “local application” means (e.g., by using a hand or applicator) directly smearing / coating onto the outside of human tissue (including hair, skin).

[0036] Unless otherwise stated, all percentages mentioned herein are weight percentages, and all references cited herein are incorporated in their entirety by way of citation.

[0037] Cosmetic Composition

[0038] A cosmetic composition is a product or formulation that contains multiple ingredients and is designed to enhance or improve appearance through makeup or cosmetic procedures.

[0039] According to one aspect, this disclosure provides a cosmetic composition comprising an extract of *Essencephalotaxus fortunei* and at least one fluorescence enhancer.

[0040] Cosmetic compositions can have various pH values. In the absence of a pH adjuster, the pH of the cosmetic composition is primarily determined by the amounts of the EP extract and the fluorescence enhancer, and within the range of EP extract and fluorescence enhancer content described below, the pH range of the cosmetic composition is from about 6.0 to about 10.0, preferably from about 6.5 to about 9.8, and more preferably from about 7.0 to about 9.7. In the presence of a pH adjuster, to avoid the potential impact of excessive acidity or alkalinity on the fluorescence enhancement effect, the pH of the cosmetic composition can be suitably set from about 5.0 to about 10.0.

[0041] Extract of Eisenia fetida

[0042] The bluewood, also known as the kidneywood, is a tree native to Mexico that grows along forest edges and riverbanks at altitudes of 150 to 3000 meters.

[0043] In some embodiments, the *Eisenia fetida* extract is selected from flower extracts, fruit extracts, stem extracts, leaf extracts, root extracts, and mixtures thereof.

[0044] Preferably, the extract of *Essencephalotaxus fortunei* is a stem extract of *Essencephalotaxus fortunei*.

[0045] More preferably, the stem extract of *Essencephalotaxus fortunei* is a bark extract of *Essencephalotaxus fortunei*.

[0046] As used in this article, the term "bark" refers to all tissues outside the vascular cambium of the stem and that serve as a protective structure around the trunk.

[0047] In some embodiments, the extract of *Essenia multispinata* is obtained by extraction using a solvent selected from lower saturated alkyl alcohols, water, and mixtures thereof.

[0048] As used herein, the term “lower saturated alkyl alcohol” refers to a saturated monohydric or polyhydric alcohol having 1 to 4 carbon atoms.

[0049] Examples of monohydric alcohols include methanol, ethanol, propanol, isopropanol, n-butanol, isobutanol, and tert-butanol.

[0050] Examples of polyols include ethylene glycol, propylene glycol, butylene glycol, and glycerol.

[0051] Preferably, the extract of *Eisenia fetida* is obtained by extraction using a solvent selected from methanol, ethanol, ethylene glycol, propylene glycol, butylene glycol, glycerol, water, and mixtures thereof.

[0052] More preferably, the extract of *Eisenia fetida* is obtained by extraction using a mixture of propylene glycol and water as a solvent. Preferably, the ratio of propylene glycol to water in the mixture is about 1:10 to about 10:1, more preferably about 1:5 to 5:1, and more preferably about 1:2 to 2:1.

[0053] Without expecting to be bound by any particular theory, it is believed that the fluorescence enhancers described below can enhance the luminescence intensity of EP extracts through intermolecular interactions with fluorescent luminescent groups in EP extracts, thereby enhancing the skin-brightening effect of EP extracts.

[0054] Non-limiting examples of Eysenhardtia polystachya extract include bark extracts of Eysenhardtia polystachya obtained by water / propylene glycol extraction, such as those purchased from Ashland under the trade name Eysenhardtia polystachya extract.

[0055] Fluorescence enhancer

[0056] As used herein, the term "fluorescence enhancer" is not particularly limited, as long as it can enhance the fluorescence intensity of the EP extract. To achieve excellent fluorescence enhancement and skin brightening effects, the fluorescence intensity of the EP extract needs to be enhanced by at least 5 times, preferably at least 10 times.

[0057] Preferably, the fluorescence enhancer can enhance the fluorescence intensity of the EP extract by 11 times or more, preferably 12 times or more.

[0058] In some embodiments, the fluorescence enhancer is at least one selected from histidine, lysine, matrine, polylysine, and arginine.

[0059] Non-limiting examples of sodium hydroxide include 30% aqueous sodium hydroxide solution (e.g., a product purchased from ShangHai GaoXin Chemical Glass Instrument Co., Ltd., under the trade name Caustic Soda 30%).

[0060] Histidine is a compound with the following chemical structure.

[0061]

[0062] It exists in nature in its enantiomer form L. However, in this disclosure, the term "histidine" includes any of its enantiomers.

[0063] Lysine is an α-amino acid with the following chemical structure.

[0064]

[0065] It exists in nature in its enantiomer form L. However, in the context of this disclosure, the term "lysine" includes any of its enantiomers.

[0066] A non-limiting example of lysine is a product purchased from Macklin under the trade name Lysine.

[0067] Arginine refers to compounds with the following chemical structure.

[0068]

[0069] It exists in nature in its enantiomer form L. However, in the context of this disclosure, the term "arginine" includes any of its enantiomers.

[0070] Non-limiting examples of arginine are commercial products purchased from Ajinomoto Co., Inc. under the trade name L-Arginine C-Grade.

[0071] Matrine is an alkaloid with the following chemical structure.

[0072]

[0073] In the context of this disclosure, the term "matrine" includes any of its enantiomers.

[0074] Non-limiting examples of matrine include commercial products purchased from Matrine under the trade name Matrine.

[0075] Polylysine refers to lysine-based polymers with the following chemical structure.

[0076]

[0077] Where n represents the polymerization number of lysine, and can be determined based on the molecular weight of polylysine.

[0078] In some implementations, polylysine is a polymer based on L-lysine.

[0079] In some embodiments, the polylysine is selected from α-polylysine, ε-polylysine, hyperbranched polylysine, and dendritic polylysine, preferably from ε-polylysine and / or dendritic polylysine.

[0080] In some embodiments, the molecular weight of polylysine is equal to or greater than 200, even equal to or greater than 300, or equal to or greater than 400, preferably equal to or greater than 500, or equal to or greater than 800; and / or the molecular weight of polylysine is equal to or less than 200,000, even equal to or less than 150,000, or equal to or less than 100,000, preferably equal to or less than 50,000, or equal to or less than 20,000; and / or the molecular weight of polylysine is 200 to 200,000, even 400 to 10,000, or 600 to 50,000, or 800 to 20,000, or 1,000 to 15,000, preferably 1,000 to 10,000.

[0081] A non-limiting example of polylysine is ε-polylysine purchased from Chisso Corp. under the trade name Polylysine 25% solution.

[0082] To achieve better fluorescence intensity enhancement, the fluorescence enhancer is preferably selected from at least one of lysine, matrine, polylysine, and arginine.

[0083] In some embodiments, the content of *Essencephalotaxus fortunei* extract is from about 0.001% to about 50% by weight, based on the total weight of the cosmetic composition.

[0084] Not expecting to be bound by any particular theory, it is believed that if the content of EP extract is too low, sufficient brightening effect may not be achieved, and the visual appearance of skin blemishes may not be adequately reduced, while if the content is too high, safety issues may arise. Therefore, the content of *Essencephalotaxus fortunei* extract is preferably from about 0.01% by weight to about 10% by weight, more preferably from about 0.1% by weight to about 2% by weight.

[0085] In some embodiments, the content of at least one fluorescent enhancer is from about 0.0001% by weight to about 50% by weight, preferably from about 0.001% by weight to about 10% by weight, and more preferably from about 0.01% by weight to about 2% by weight, based on the total weight of the cosmetic composition.

[0086] In some embodiments, the cosmetic composition has an extract of *Essencephalotaxus fortunei* and a fluorescence enhancer in a weight ratio of about 5000:1 to about 1:100.

[0087] Without being bound by any particular theory, it is believed that if the amount of fluorescence enhancer relative to the EP extract is too small, sufficient fluorescence enhancement cannot be achieved, while if the amount is too large, no additional enhancement effect will be produced, which is economically undesirable. Therefore, the cosmetic composition preferably has a weight ratio of *Essentialia foetida* extract to fluorescence enhancer of about 500:1 to about 1:10, and more preferably about 50:1 to about 1:1.

[0088] Other ingredients

[0089] Cosmetic compositions may be in solid, semi-solid, or liquid form, and may be in the form of solutions, emulsions, suspensions, or anhydrous forms. If in solution or suspension form, the composition may contain about 1% to about 99.9%, preferably about 5% to about 95%, more preferably about 10% to about 90% water. If in emulsion form, the composition may contain about 1% to about 99%, preferably about 5% to about 90%, more preferably about 10% to about 85% water and about 1% to about 99%, preferably about 5% to about 90%, more preferably about 5% to about 75% oil. If in anhydrous form, the composition may contain about 10% to about 99% oil and about 10% to about 99% solidifying agent.

[0090] Provided that the purposes of this disclosure are achieved, cosmetic compositions may also contain at least one cosmetically acceptable active ingredient, such as a moisturizer, antioxidant, UV shielding agent, anti-inflammatory agent, preservative, vitamin, skin conditioning agent, or stabilizer, particularly for the prevention or reduction of excessive sebum, acne, wrinkles, fine lines, dry skin, photoaging, and inflammation. Other cosmetically acceptable ingredients that may be mentioned include oils, thickeners, pH adjusters, or any other ingredients commonly formulated into cosmetics or pharmaceuticals. Non-limiting examples of some of these ingredients are provided in the following subsections.

[0091] A. Moisturizer

[0092] The compositions disclosed herein may contain one or more humectants. If present, they may comprise about 0.1% to about 75% of the total weight of the composition, preferably about 0.2% to about 70%, more preferably about 0.5% to about 40%. Examples of suitable humectants include glycols, sugars, hyaluronic acid, sodium hyaluronate, etc. Preferably, the humectants used in the compositions disclosed herein are C1-8, preferably C2-4 alkylene glycols, such as octane glycol, hexane glycol, and butylene glycol.

[0093] Suitable sugars, some of which are also polyols, are also suitable humectants. Examples of such sugars include glucose, fructose, honey, hydrogenated honey, inositol, maltose, mannitol, maltitol, sorbitol, sucrose, xylitol, xylose, trehalose, etc. Sugar derivatives are also suitable, such as ethylhexylglycerin.

[0094] In some preferred embodiments, the humectants used in the composition are C1-6, preferably C2-4 alkylene glycols, most particularly butylene glycol and / or ethylhexylglycerin.

[0095] B. Antioxidants

[0096] The compositions disclosed herein may contain one or more antioxidants. If present, they may comprise about 0.001 to about 20% of the total weight of the composition, preferably about 0.005 to about 15%, more preferably about 0.010 to about 10%.

[0097] Non-limiting examples of antioxidants that may be used in the compositions disclosed herein include acetylcysteine, ascorbic acid peptides, ascorbate dipalmitate, ascorbate methylsilanol pectate, ascorbate palmitate, ascorbate stearate, BHA, BHT, tert-butylhydroquinone, cysteine, cysteine ​​HCl, dipentylhydroquinone, di-tert-butylhydroquinone, dicerylthiodipropionate, disodium ascorbate sulfate, distearate thiodipropionate, di(tridecyl)thiodipropionate, dodecyl gallate, isoascorbic acid, ascorbate, ethyl ferulic acid, ferulic acid, gallic acid, etc. Esters, hydroquinone, isooctyl mercaptoacetate, kojic acid, magnesium ascorbate, magnesium ascorbate phosphate, methylsilanol ascorbate, natural plant antioxidants (such as green tea or grape seed extract), nordihydroguaiac acid, octyl gallate, phenyl thioglycolic acid, potassium sulfite, propyl gallate, quinones, rosmarinic acid, sodium ascorbate, sodium bisulfite, sodium isoascorbate, sodium metabisulfite, sodium sulfite, superoxide dismutase, sodium thioglycolate, sorbitan furfural, diethylene thioglycol, thiodiethanolamide, thiodiethanolic acid, thioglycolic acid, thiolactic acid, thiosalicylic acid, and tris(nonylphenol) phosphite.

[0098] C. UV shielding agent

[0099] The compositions disclosed herein may contain one or more UV-blocking agents. If present, the UV-blocking agent may comprise about 0.1% to about 50% of the total weight of the composition, preferably about 0.5% to about 40%, more preferably about 1% to about 35%.

[0100] Non-limiting examples of UV shielding agents include chemical UVA shielding agents such as benzoylmethane compounds and camphor sulfonic acid derivatives, or UVB shielding agents such as phenylbenzimidazole sulfonic acid, 2-cyano-3,3-diphenylacrylate 2-ethylhexyl ester, ethylhexyl methoxycinnamate, benzophenone derivatives, menthol salicylate derivatives, or physical shielding agents in particulate form. Including a shielding agent in the composition will provide additional protection to the skin during sunlight exposure and enhance the effectiveness of whitening active ingredients on the skin.

[0101] As needed, the compositions disclosed herein can be formulated to have a certain SPF (Sun Protection Factor) value, ranging from about 1 to about 50, or even 50+, depending on the type and dosage of the UV shielding agent. The calculation of SPF values ​​is well known in the art.

[0102] D. Anti-inflammatory agents

[0103] The compositions disclosed herein may contain one or more anti-inflammatory agents. If present, the anti-inflammatory agent may comprise about 0.001% to about 5% of the total weight of the composition, preferably about 0.01% to about 2%, more preferably about 0.1% to about 1%.

[0104] Non-limiting examples of anti-inflammatory agents include steroidal and non-steroidal anti-inflammatory agents. Steroidal anti-inflammatory agents can be hydrocortisone. So-called "natural" anti-inflammatory agents are also available. For example, bisabolol, aloe vera, manjistha (extracted from plants of the genus Rubia, particularly Rubia cordifolia), and quince (extracted from plants of the genus Myrrh, particularly Indian myrrh), kola nut extract, chamomile, and sea whip extract are also available.

[0105] The inclusion of anti-inflammatory agents in the composition will enhance skin appearance benefits, for example, by contributing to evenness and acceptable skin tone and / or color.

[0106] E. Preservatives

[0107] The compositions disclosed herein may contain one or more preservatives. If present, the preservatives may comprise about 0.001% to about 8% of the total weight of the composition, preferably about 0.01% to about 6%, more preferably about 0.05% to about 5%.

[0108] Non-limiting examples of preservatives that can be used in the compositions of this disclosure include quaternary ammonium preservatives, such as polyquaternary ammonium salt-1 and benzalkonium halide (e.g., benzalkonium chloride (“BAC”) and benzalkonium bromide), parabens (e.g., methylparaben and propylparaben), phenoxyethanol, benzyl alcohol, chlorobutanol, phenol, calcium benzoate, sodium benzoate, sorbic acid, thimerosal, or combinations thereof.

[0109] F. Vitamins

[0110] The compositions disclosed herein may contain one or more vitamins. If present, the vitamins may comprise about 0.001% to about 20% of the total weight of the composition, preferably about 0.005% to about 15%, more preferably about 0.1% to about 10%.

[0111] Non-limiting examples of vitamins that may be used in the compositions disclosed herein include tocopherol or its derivatives, such as tocopherol acetate, tocopherol ferulic acid ester, tocopherol polyether-5, tocopherol polyether-10, tocopherol polyether-12, tocopherol polyether-18, tocopherol polyether-50, tocopherol, tocopherol enol ester, tocopherol linoleate, tocopherol nicotinate, tocopherol succinate dioleoyltocopherol methylsilanol; ascorbic acid or its derivatives, such as ascorbate palmitate, ascorbate magnesium phosphate; vitamin A or its derivatives, such as retinyl palmitate; or vitamins D, K, B or their derivatives.

[0112] G. Conditioner

[0113] The compositions disclosed herein may contain one or more skin / hair conditioning agents. If present, the skin conditioning agent may comprise about 0.001% to about 10% of the total weight of the composition, preferably about 0.01% to about 5%, more preferably about 0.1% to about 2%.

[0114] Non-limiting examples of skin / hair conditioning agents that can be used in the compositions of this disclosure include RNA-Na (sodium ribonucleic acid); vitamin B5 derivatives such as panthenol, dextropanthenol, panthenyl thioethylamine, lauroyl lysine, hydrolyzed keratin, and hydrolyzed wheat protein.

[0115] H. Stabilizer

[0116] The compositions disclosed herein may contain one or more stabilizers. If present, the stabilizer may comprise about 0.001% to about 10% of the total weight of the composition, preferably about 0.01% to about 5%, more preferably about 0.1% to about 2%.

[0117] Non-limiting examples of stabilizers that can be used in the compositions of this disclosure include sodium gluconate, sodium phytate, disodium EDTA, trisodium EDTA, and tetrasodium EDTA.

[0118] Non-limiting examples of stabilizers that can be used in the compositions of this disclosure also include silicone surfactants, such as those sold by Dow Corning under the trade name Dow Corning 3225C Formulation Aid, with the CTFA names cyclotetrasiloxane (and)cyclopentasiloxane (and) PEG / PPG-18 polydimethylsiloxane; or 5225C Formulation Aid, with the CTFA names cyclopentasiloxane (and) PEG / PPG-18 / 18 polydimethylsiloxane; or Dow Corning 190 Surfactant, with the CTFA name PEG / PPG-18 / 18 polydimethylsiloxane; or Dow Corning 193 Fluid, Dow Corning 5200, with the CTFA name lauryl PEG / PPG-18 / 18 polymethylsiloxane; or Abil EM sold by Goldschmidt with the CTFA name cetyl PEG / PPG-14 / 14 polydimethylsiloxane. 90; or Abil EM 97, sold by Goldschmidt, with the CTFA name of bis-cetyl PEG / PPG-14 / 14 polydimethylsiloxane; or Abil WE 09, sold by Goldschmidt, with the CTFA name of cetyl PEG / PPG-10 / 1 polydimethylsiloxane, in a mixture also containing polyglycerol-4 isostearate and hexyl laurate; or KF-6011, sold by Shin-Etsu Silicones, with the CTFA name of PEG-11 methyl ether polydimethylsiloxane; KF-6012, sold by Shin-Etsu Silicones, with the CTFA name of PEG / PPG-20 / 22 butyl ether polydimethylsiloxane; or KF-6013, sold by Shin-Etsu Silicones, with the CTFA name of PEG-9 polydimethylsiloxane; or by Shin-Etsu KF-6015 sold by Silicones has the CTFA name PEG-3 polydimethylsiloxane; or KF-6016 sold by Shin-Etsu Silicones has the CTFA name PEG-9 methyl ether polydimethylsiloxane; or KF-6017 sold by Shin-Etsu Silicones has the CTFA name PEG-10 polydimethylsiloxane; or KF-6038 sold by Shin-Etsu Silicones has the CTFA name lauryl PEG-9 polydimethylsiloxane ethyl polydimethylsiloxane.

[0119] I. Surfactants

[0120] The compositions disclosed herein may contain one or more surfactants, particularly in emulsion form. However, such surfactants may be used if the composition is also a solution, suspension, or anhydrous. If present, the surfactant may comprise about 0.01 to about 30% of the total weight of the composition, preferably about 0.05 to about 25%, more preferably about 0.1 to about 20%.

[0121] Non-limiting examples of surfactants that may be used in the compositions of this disclosure include nonionic organic surfactants such as Oleth-3, Oleth-5, Oleth-3 phosphate, Choleth-24, Ceteth-24, methyl gluceth-20; glycerol ether-26, PEG-75; silicone or silyl surfactants such as PEG-1 polydimethylsiloxane, PEG-4 polydimethylsiloxane, PEG-8 polydimethylsiloxane, PEG-12 polydimethylsiloxane, PEG-20 polydimethylsiloxane, bis-PEG-18 methyl ether dimethylsilane, polydimethylsiloxane copolyols; hexadecyl polydimethylsiloxane copolyols, etc.

[0122] Other suitable nonionic surfactants include alkoxylated sorbitol and alkoxylated sorbitol derivatives. For example, alkoxylation of sorbitol, particularly ethoxylation, provides polyalkoxylated sorbitol derivatives. Esterification of polyalkoxylated sorbitol provides sorbitol esters, such as polysorbate esters. For example, polyalkoxylated sorbitol can be esterified with C6-30, preferably C12-22 fatty acids. Examples of such components include polysorbate esters 20-85, sorbitol oleate, sorbitol sesquioleate, sorbitol palmitate, sorbitol sesquiisostearate, sorbitol stearate, etc.

[0123] J. Thickener

[0124] A suitable thickener may be incorporated into the compositions disclosed herein. If present, the suggested range is about 0.01% to about 30% of the total weight of the composition, preferably about 0.1% to about 20%, more preferably about 0.5% to about 15%.

[0125] Non-limiting examples of thickeners that can be used in the compositions of this disclosure include animal, plant, mineral, silicone, or synthetic waxes; silica, silicates, silica silyl alkylates, and their alkali metal or alkaline earth metal derivatives; silicone elastomers such as vinyl polydimethylsiloxane / methyl polysiloxane silsesquioxane crosspolymers; and polysaccharides such as agar, agarose, hyaluronic acid, hydroxyethyl cellulose, methyl cellulose, ethyl cellulose, pectin, sclerotinum gum, xanthan gum, dehydroxanthan gum, pectin, trehalose, gelatin, etc.

[0126] Acrylic ester copolymers are also applicable, such as polyacrylate-3, which is a copolymer of methacrylic acid, methyl methacrylate, methyl styrene isopropyl isocyanate and PEG-40 behenate monomers; polyacrylate-10, which is a copolymer of sodium acryloyl dimethyl taurate, sodium acrylate, acrylamide and vinylpyrrolidone monomers; or polyacrylate-11, which is a copolymer of sodium acryloyl dimethyl taurate, sodium acrylate, hydroxyethyl acrylate, lauryl acrylate, butyl acrylate and acrylamide monomers.

[0127] Polymers based on crosslinked acrylates are also suitable, wherein one or more acrylate groups may have substituted long-chain alkyl groups (e.g., 6-40, 10-30, etc.), such as acrylate / C10-30 alkyl acrylate crosslinked polymers, which are copolymers of C10-30 alkyl acrylates with one or more acrylic acid, methacrylic acid monomers, or simple esters thereof, crosslinked with sucrose allyl ether or pentaerythritol allyl ether. Such polymers are commonly sold under the trade names Carbopol or Pemulen, and their CTFA name is Carbopol.

[0128] K. Oil

[0129] When the compositions disclosed herein are in the form of solutions, suspensions, anhydrous forms, and particularly emulsions, the compositions may contain oil components. Oil components are desirable for skin moisturizing and protective properties. Suitable oils include volatile silicones, such as Dow Corning 244, 245, 344, and 200 fluids; volatile alkanes, such as pentane, hexane, heptane, decane, dodecane, tetradecane, tridecane, and C8-20 isoalkanes, as disclosed in U.S. Patent Nos. 3,439,088 and 3,818,105 (both of which are incorporated herein by reference); mono, di, and triesters, such as hexyl laurate, butyl isostearate, diisostearyl malate, neopentyl glycol dioctanoate, tributyl citrate, and triisostearyl citrate; hydrocarbon oils, such as mineral oil, pentahydrosqualene, squalene, and squalane; non-volatile oils, such as polydimethylsiloxane, phenyl polydimethylsiloxane, diphenyl polydimethylsiloxane, phenyl polytrimethylsiloxane, or trimethylsiloxyphenyl polydimethylsiloxane; and so on.

[0130] L. Particulate materials

[0131] The compositions disclosed herein may contain particulate material in the form of pigments, inert particles, or mixtures thereof. If present, the particulate material may be from about 0.01 to about 75% of the total weight of the composition, preferably from about 0.5 to about 70%, more preferably from about 0.1 to about 65%. In cases where the composition may contain a mixture of pigments and powders, suitable ranges include about 0.01 to about 75% pigment and about 0.1 to about 75% powder, based on the total weight of the composition.

[0132] Particulate matter can be colored or colorless powder. Suitable non-colored powders include bismuth oxychloride, titanate mica, fumed silica, spherical silica, polymethyl methacrylate, micronized polytetrafluoroethylene, boron nitride, acrylate copolymers, aluminum silicate, aluminum octenyl succinate, bentonite, calcium silicate, cellulose, chalk, corn starch, diatomaceous earth, bleaching clay, glycerol starch, lithium montmorillonite, hydrated silica, kaolin, magnesium aluminum silicate, magnesium trisilicate, maltodextrin, montmorillonite, microcrystalline cellulose, rice starch, silica, talc, mica, titanium dioxide, zinc laurate, zinc myristate, zinc rosinate, alumina, attapulgite, calcium carbonate, calcium silicate, dextran, kaolin, nylon, silyl alkylated silica, silk powder, sericite, soybean flour, tin oxide, titanium hydroxide, magnesium triphosphate, walnut shell powder, or mixtures thereof. The powder can be surface-treated with lecithin, amino acids, mineral oil, silicone or various other reagents, alone or in combination, to coat the powder surface and make the particles more lipophilic.

[0133] Those skilled in the art can select the amount of these ingredients according to the end use of the cosmetic composition. Those skilled in the art will understand that the composition according to this disclosure may contain one or more additional cosmetically acceptable ingredients comprising about 20% to about 98%, preferably about 30% to about 90%, more preferably about 40% to about 80% of the total weight of the composition.

[0134] Cosmetic compositions can be in any form. Suitable forms include, but are not limited to, solids, liquids, gels, lotions, creams, hard gel sticks, roll-on formulations, mousses, aerosol sprays, pad-on formulations, and film-forming formulations.

[0135] The cosmetic compositions disclosed herein can also be widely used in the fields of personal care, food, dietary supplements and pharmaceuticals.

[0136] Other aspects

[0137] According to another aspect, this disclosure provides cosmetics comprising cosmetic compositions according to this disclosure.

[0138] According to another aspect, this disclosure provides the use of cosmetic compositions according to this disclosure in the manufacture of cosmetics for reducing the visual perception of skin defects, said skin defects being selected from yellowing, dullness, uneven skin tone, dark circles, pigmentation, rosacea, fine lines, wrinkles, enlarged pores, and cellulite.

[0139] According to another aspect, this disclosure provides a cosmetic method for reducing the visual perception of skin defects selected from yellowing, dullness, uneven skin tone, dark circles, pigmentation, rosacea, fine lines, wrinkles, enlarged pores, and cellulite, comprising topically applying the composition of this disclosure to the skin.

[0140] This invention is not limited to these embodiments, but can be modified by those skilled in the art within the scope of the appended claims. The invention also encompasses any embodiment obtained by combining the technical means disclosed in the different embodiments.

[0141] Example

[0142] The following examples are given as non-limiting illustrations of the present invention.

[0143] The main raw materials used, their product names, INCI names, and suppliers are listed in Table 1.

[0144]

[0145]

[0146] Example 1: Absorption and emission properties of extracts from *Echinopsis multiflora*.

[0147] For the 0.1% by weight aqueous solution of the *Echinopsis multiflora* (EP) extract listed in Table 1, the absorption and fluorescence spectra excited at 370 nm in 6-well plates were recorded using a Tecan microplate reader A-5082.

[0148] like Figure 1 As shown, the EP extract absorbs light in the ultraviolet region (approximately 230 nm to 400 nm) of the electromagnetic spectrum and re-emits light in the visible light region (approximately 400 nm to approximately 630 nm), with a peak at approximately 466 nm.

[0149] Example 2: Fluorescence intensity test of combinations containing EP extracts

[0150] According to the compositions in Table 2, the EP extract was mixed with various fluorescence enhancers at concentrations of 0.5% and 0.1% in 2 mL of aqueous solution. The fluorescence intensity of each solution excited at 370 nm in a 6-well plate was measured at 466 nm using a Tecan microplate reader A-5082.

[0151] The fluorescence intensity of the individual EP extract was set to 1, and the fluorescence enhancement performance of each combination was evaluated by dividing the measured fluorescence intensity by the fluorescence intensity of the individual EP extract. The results are shown in Table 2.

[0152] Table 2. Fluorescence intensity of the combination of EP extract and enhancer

[0153]

[0154] It can be seen that the fluorescence intensity of EP extract is enhanced by combining it with specific fluorescence enhancers. The fluorescence intensity of combinations containing lysine, matrine, arginine, histidine or polylysine is enhanced by more than 10 times, showing excellent fluorescence enhancement performance.

[0155] Fluorescence intensity test of the combination containing EP extract in Comparative Example 1

[0156] Except that the fluorescence enhancer was replaced with the substances shown in Table 3, the fluorescence enhancement performance was evaluated in the same manner as in Example 2.

[0157] Table 3. Fluorescence intensity of combinations of EP extract and other substances

[0158]

[0159]

[0160] It can be seen that when the fluorescence enhancer is replaced with other substances, the fluorescence intensity of the combination decreases to some extent without being enhanced.

[0161] Example 3: Quantum testing of combinations containing EP extracts

[0162] For each material listed in Table 4, fluorescence efficiency is measured by quantum yield Φ:

[0163]

[0164] It is determined by the relative rates of fluorescence emission and the competing processes. The quantum yield of the fluorophore was determined using an Edinburgh FLS1000.

[0165] Table 4. Comparison of EP extract with commercially available skin brightening products

[0166]

[0167] As shown in Table 4, the quantum yield of the EP extract is significantly higher than that of the commercially available skin brightening product IBR-dragon. Furthermore, the combined use with lysine or polylysine can greatly improve the quantum yield of the EP extract, increasing it from 53.23% to 70.19% and 76.04%, respectively, consistent with the fluorescence intensity results in Example 2.

[0168] Example 4: Fluorescence enhancement performance test of combinations of EP extract and fluorescence enhancer in different ratios.

[0169] In addition to using the compositions in Table 5, the fluorescence enhancement performance was evaluated in the same manner as in Example 2.

[0170] Table 5. Fluorescence intensity of combinations of EP extract and enhancer at different ratios

[0171]

[0172] As shown in Table 5, fluorescence enhancement can be achieved even at extremely low ratios of 1 / 5000 relative to the EP extract by using the fluorescence enhancer in the composition disclosed herein.

[0173] Comparative Example 2: Fluorescence intensity test of a combination containing commercially available skin brightening products

[0174] Except that the EP extract was replaced with the commercially available skin brightening product IBR dragon, the fluorescence enhancement performance was evaluated in the same manner as in Example 2.

[0175] Table 6. Fluorescence Intensities of IBR Dragon and Enhancers

[0176]

[0177] As shown in Table 6, combining it with a fluorescence enhancer does not enhance the fluorescence of the commercially available skin brightening product IBR-dragon.

[0178] The EP extract according to this disclosure, combined with at least one fluorescence enhancer, can be formulated into a preparation using conventional methods and common carriers, auxiliaries, or excipients. Exemplary formulations and their preparation methods are given below. All ingredients used in the formulations are well known in the art and commercially available.

[0179] Example 5: Fluorescence intensity test of combinations containing EP extracts at different pH values.

[0180] Except that the pH of the EP extract solution (0.5 wt%) was adjusted to the same level using the composition in Table 7, the fluorescence enhancement performance was evaluated in the same manner as in Example 2.

[0181] As shown in Table 6, even at the same pH value, the polylysine group has better fluorescence enhancement performance than the caustic soda group.

[0182] Table 7. Fluorescence enhancement performance at different pH values

[0183]

[0184] Formulation Example 1

[0185] The serum formulation according to this disclosure is prepared as follows:

[0186]

[0187]

[0188] 1) Add the components from sequence 1 to the bulk, heat to 50°C and homogenize to obtain a homogeneous solution (homogenization speed should be <1500 rpm to avoid generating bubbles).

[0189] 2) Cool the mixture to room temperature in a homogeneous state.

[0190] 3) Premix the ingredients from step 2 and add them to the main component. (The liquid will become clear after adding this mixture.)

[0191] 4) Premix the components of sequence 3 and add them to the main body in a homogeneous state.

[0192] 5) In a homogeneous state, add the component of sequence 4 to the main body.

[0193] 6) In a homogeneous state, add the component of sequence 5 to the main body.

[0194] 7) In a homogeneous state, add the component of sequence 6 to the main body.

[0195] 8) In a homogeneous state, add the component of sequence 7 to the main body.

[0196] 9) In a homogeneous state, add the component of sequence 8 to the main body.

[0197] 10) In a homogeneous state, add the component of sequence 9 to the main body.

[0198] 11) Premix the components of sequence 2 and add them to the main body in a homogeneous state.

[0199] Although this disclosure and its advantages have been described in detail, it should be understood that various changes, substitutions, and modifications may be made herein without departing from the spirit and scope of this disclosure as defined by the appended claims. Furthermore, the scope of this application is not intended to be limited to the specific embodiments of the methods, machines, manufactures, material compositions, apparatuses, methods, and steps described in the specification. As will be readily understood by those skilled in the art from this disclosure, methods, machines, manufactures, material compositions, apparatuses, methods, or steps, whether existing or later developed, can be used to perform substantially the same function or achieve substantially the same results as the corresponding embodiments described herein. Therefore, the appended claims are intended to include such methods, machines, manufactures, material compositions, apparatuses, methods, or steps within their scope.

Claims

1. A cosmetic composition comprising an extract of *Echinopsis pilosula* and at least one fluorescence enhancer selected from sodium hydroxide, urea, betaine, nicotinamide, chitosan, histidine, lysine, matrine, polylysine, and arginine.

2. The cosmetic composition according to claim 1, wherein the *Essencephalotaxus fortunei* extract is selected from the flower extract, fruit extract, stem extract, leaf extract, and root extract of *Essencephalotaxus fortunei*. Preferably, the *Eisenia fetida* extract is a stem extract of *Eisenia fetida*. More preferably, the stem extract of *Eisenia fetida* is a bark extract of *Eisenia fetida*.

3. The cosmetic composition according to claim 1 or 2, wherein, The extract was obtained by extraction with a solvent selected from lower saturated alkyl alcohols, water, and mixtures thereof. Preferably, the extract is obtained by extraction using methanol, ethanol, ethylene glycol, propylene glycol, butylene glycol, glycerol, water, or mixtures thereof as solvents. More preferably, the extract is obtained by extraction using a mixture of propylene glycol and water as a solvent. Preferably, the ratio of propylene glycol to water in the mixture is 1:10-10:1, more preferably 1:5-5:1, and even more preferably 1:2-2:

1.

4. The cosmetic composition according to any one of claims 1 to 3, wherein, The fluorescence enhancer is selected from at least one of histidine, lysine, matrine, polylysine, and arginine. Preferably, the fluorescence enhancer is at least one selected from lysine, matrine, polylysine, and arginine.

5. The cosmetic composition according to any one of claims 1 to 4, wherein, The weight ratio of the extract of *Essencephalotaxus fortunei* to the fluorescence enhancer in the cosmetic composition is about 5000:1 to about 1:100, preferably about 500:1 to about 1:10, and more preferably about 50:1 to about 1:

1.

6. The cosmetic composition according to any one of claims 1 to 5, wherein, Based on the total weight of the cosmetic composition, the content of the *Essencephalotaxus fortunei* extract is from about 0.001% to about 50% by weight, preferably from about 0.01% to about 10% by weight, and more preferably from about 0.1% to about 2% by weight.

7. The cosmetic composition according to any one of claims 1 to 6, wherein, Based on the total weight of the cosmetic composition, the content of the at least one fluorescent enhancer is from about 0.0001% by weight to about 50% by weight, preferably from about 0.001% by weight to about 10% by weight, more preferably from about 0.01% by weight to about 2% by weight.

8. The cosmetic composition according to any one of claims 1 to 7, wherein, The cosmetic composition further comprises at least one active ingredient selected from moisturizers, antioxidants, UV shielding agents, anti-inflammatory agents, preservatives, vitamins, skin conditioning agents, stabilizers, and mixtures thereof.

9. A cosmetic product comprising a cosmetic composition according to any one of claims 1 to 8.

10. Use of the cosmetic composition according to any one of claims 1 to 8 in the manufacture of a cosmetic for reducing the visual perception of skin defects, said skin defects being selected from yellowing, dullness, uneven skin tone, dark circles, pigmentation, rosacea, fine lines, wrinkles, enlarged pores, and cellulite.

11. A cosmetic method for reducing the visual perception of skin defects, said skin defects being selected from yellowing, dullness, uneven skin tone, dark circles, pigmentation, rosacea, fine lines, wrinkles, enlarged pores, and cellulite, comprising applying to the skin a composition according to any one of claims 1 to 8 or a cosmetic according to claim 9.

Images